155 related articles for article (PubMed ID: 34668451)
1. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Ramos Perez JM; Patel KP; Loghavi S; Garcia-Manero G; Borthakur G; Jabbour E; Wierda W; Pierce S; Brandt M; Kornblau S; Kadia T; Daver N; DiNardo CD; Jain N; Yilmaz M; Short N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Rivera D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2022 Mar; 63(3):672-675. PubMed ID: 34668451
[TBL] [Abstract][Full Text] [Related]
2. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Grimwade D; Jovanovic JV; Hills RK; Nugent EA; Patel Y; Flora R; Diverio D; Jones K; Aslett H; Batson E; Rennie K; Angell R; Clark RE; Solomon E; Lo-Coco F; Wheatley K; Burnett AK
J Clin Oncol; 2009 Aug; 27(22):3650-8. PubMed ID: 19506161
[TBL] [Abstract][Full Text] [Related]
3. Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
Chendamarai E; Balasubramanian P; George B; Viswabandya A; Abraham A; Ahmed R; Alex AA; Ganesan S; Lakshmi KM; Sitaram U; Nair SC; Chandy M; Janet NB; Srivastava VM; Srivastava A; Mathews V
Blood; 2012 Apr; 119(15):3413-9. PubMed ID: 22374701
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
5. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
Reiter A; Lengfelder E; Grimwade D
Acta Haematol; 2004; 112(1-2):55-67. PubMed ID: 15179005
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
8. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
9. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia in childhood.
Gregory J; Feusner J
Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
[TBL] [Abstract][Full Text] [Related]
11. Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
Hasan SK; Lo-Coco F
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10 Suppl 3():S139-43. PubMed ID: 21115433
[TBL] [Abstract][Full Text] [Related]
12. Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
Zhang L; Cao Z; Zou Y; Ruan M; Li Q; Wang J; Zhu X
Int J Hematol; 2012 May; 95(5):500-8. PubMed ID: 22407853
[TBL] [Abstract][Full Text] [Related]
13. A short report of novel
Song Y; Hou J; Wan L; Liu K; Zhou C; Wei S; Zhang G; Lin D; Li Y; Fang Q; Liu Y; Gong B; Gong X; Wang Y; Wei H; Wang J; Mi Y
Hematology; 2022 Dec; 27(1):518-522. PubMed ID: 35544458
[TBL] [Abstract][Full Text] [Related]
14. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
[TBL] [Abstract][Full Text] [Related]
17. Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report.
Dalvi RC; Mandava S; Pais AP; Kokate PP; Sinha N; Nath UK
Indian J Cancer; 2022; 59(3):419-421. PubMed ID: 36412315
[TBL] [Abstract][Full Text] [Related]
18. Treatment concepts of acute promyelocytic leukemia.
Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
[TBL] [Abstract][Full Text] [Related]
19. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ
Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
